期刊
CANCER RESEARCH
卷 73, 期 3, 页码 1063-1075出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-12-2583
关键词
-
类别
资金
- Nederlandse organisatie voor wetenschappelijk onderzoek (NWO) Vidi grant [917.76.363]
- EU [LSHC-CT-2006- 518234, LSHB-CT-2004-512074]
- Nijmeegs offensief tegen kanker (NOTK) foundation
- Tumor immunology laboratory (TIL) foundation
- Cancer Plan of the Belgian Federal Public Service
- NWO Spinoza prize
Vaccination against cancer by using dendritic cells has for more than a decade been based on dendritic cells generated ex vivo from monocytes or CD34(+) progenitors. Here, we report on the first clinical study of therapeutic vaccination against cancer using naturally occurring plasmacytoid dendritic cells (pDC). Fifteen patients with metastatic melanoma received intranodal injections of pDCs activated and loaded with tumor antigen-associated peptides ex vivo. In vivo imaging showed that administered pDCs migrated and distributed over multiple lymph nodes. Several patients mounted antivaccine CD4(+) and CD8(+) T-cell responses. Despite the limited number of administered pDCs, an IFN signature was observed after each vaccination. These results indicate that vaccination with naturally occurring pDC is feasible with minimal toxicity and that in patients with metastatic melanoma, it induces favorable immune responses. Cancer Res; 73(3); 1063-75. (C) 2012 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据